Why Attend?

Last Year’s Agenda
CLE

Updates for 2021

FDLI remains committed to providing high-quality educational programs while keeping our members and event attendees safe during the current pandemic. With this in mind, we are excited to announce that the 2021 Advertising and Promotion for Medical Products Conference will be a virtual event. Please know we are actively exploring options to ensure an engaging and enjoyable experience with ample opportunities to connect with your peers. Be sure to check the course website regularly for additional announcements and updates.

A virtual format will enable innovative learning opportunities, increased schedule flexibility, and a new level of interaction between regulatory practitioners, industry experts, and government officials. Speakers will analyze the latest commercial issues related to advertising and promotion of human and animal drugs, medical devices, and biologics

Practical Takeaways: Sessions will explore updated government agency enforcement trends, competitor actions, the current state of unapproved use promotion, patient engagement, management of risk in the current climate, and the increasing challenges of various direct-to-consumer marketing platforms.

Government Speakers: Representatives from various FDA Centers, the Federal Trade Commission, the Department of Health and Human Services Inspector General, and the Department of Justice will provide the latest information on policy, enforcement, and future initiatives.

Peer Interaction: The conference will prioritize virtual learning, engagement, and networking with fellow legal, regulatory, and marketing experts.

Call for Proposals – Be CREATIVE!

FDLI invites session proposals for its yearly, all-virtual Advertising and Promotion for Medical Products Conference. Topics should be at an intermediate-to-advanced level and can encompass any regulatory or practical commercial challenges related to medical products advertising or promotion.

Guidelines

  • Topics should be at an intermediate-to-advanced level.
  • Topics can relate specifically to drugs, biologics, or medical devices, veterinary medicine, or be relevant to all.
  • Topics that include a variety of perspectives and viewpoints, including government, industry, private attorneys, academics, and public interest are preferred.
  • FDLI is committed to supporting, promoting, and celebrating diversity and inclusion in the food and drug law programs. To that end, proposals addressing systematic or historical impacts on health care disparity and racial equity in relation to all areas of the FDA-regulated community are strongly encouraged.
  • Preference will be given to sessions that are designed to be interactive and/or allow for schedule flexibility to enhance a virtual format.
    • Examples: polling, pre-recorded remarks with real-time Q&A, or interactive case studies (do not feel limited to these suggestions; creativity is encouraged).
  • We prefer submissions to include a reasonably detailed and thoughtful title for and description of the proposed session.

Proposal Reminders

  • Multiple submissions from the same person or organization are welcome, but each proposal requires its own form.
  • All submissions are treated as recommendations, and proposals may be modified or combined by FDLI to best suit the needs of the conference.
  • All submissions must be received through the submission portal.
  • Speaking opportunities are generally reserved for FDLI members.

Proposal Submission Timeline

  • May 21: Call for Proposals closes.
  • June: Those who submitted proposals will be notified of their submission’s status by the end of June.
Submit

Register by October 1 and SAVE!

 

Industry & Firms

$1399
  • +$400 for non-members
  • +$100 after 10/1/21

Non-Profit

$699
  • +$100 for non-members
  • +$100 after 10/1/21

Government

$699
  • +$100 for non-members
  • +$100 after 10/1/21

Academic

$699
  • +$100 for non-members
  • +$100 after 10/1/21

Student

$149
  • full-time students only
  • transcripts required
Register Now

Sponsors

Sponsorship opportunities are available. Please let us know if you would like more information.

Gold Sponsor

 

Gold Sponsor

 

Gold Sponsor

 

Gold Sponsor

 

Silver Sponsor

 

 

Silver Sponsor

Silver Sponsor

Bronze Sponsor

 

Bronze Sponsor

 

Planning Committee

Co-Chairs

Madhavi Bellamkonda, Abbott Laboratories
Bryant M. Godfrey, Arnold & Porter LLP

Committee

Rebecca Burnett, Framework Solutions
Julie B. Chronis, Gilead Sciences, Inc.
Mary Ellen Dronitsky, Northeastern University
Virginia Foley, Opus Regulatory, Inc.
Mark Gaydos, Sanofi
Matthew Hegreness, Covington & Burling LLP
Mark Levy, Eckert Seamans Cherin & Mellott, LLC
Lauren A. Miller, AbbVie
Thomas Miller, Nixon GWILT Law
Gillian M. Russell, King & Spalding LLP
Cassie Scherer, Medtronic
Victoria Tamarkin, Tamarkin Consulting LLC
Kyle Thomson, American Medical Association